SCHEMBL2802313

SCHEMBL2802313

CCS(=O)(=O)NC(=O)c1cnn2c(Nc3cc(C)ccc3F)c(C(=O)N3CCC(c4ccc5ccccc5c4)CC3)cnc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.35
RECQL P46063 1/20 0.34
ALDH1A1 P00352 6/20 0.34
FASN P49327 4/20 0.33
CCR1 P32246 1/20 0.33
KDM4E B2RXH2 3/20 0.33
HPGD P15428 3/20 0.33
HSD17B10 Q99714 3/20 0.33
TSHR P16473 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
GLA P06280 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
USP2 O75604 2/20 0.33
POLB P06746 1/20 0.33
IRAK4 Q9NWZ3 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2800842 0.92 ALDH1A1 (0.38) EGLN1RECQLALDH1A1FASNKDM4E
SCHEMBL2799537 0.92 RECQL (0.36) EGLN1RECQLALDH1A1FASNKDM4E
SCHEMBL2801670 0.91 FASN (0.39) EGLN1RECQLALDH1A1FASNNPC1
SCHEMBL2803063 0.90 FASN (0.39) EGLN1ALDH1A1FASNKDM4EHPGD
SCHEMBL2800543 0.89 EGLN1 (0.37) EGLN1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2801458 0.88 KDM4E (0.39) RECQLALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2799817 0.88 FASN (0.36) RECQLFASNLMNAIRAK4SPR
SCHEMBL2801339 0.85 TP53 (0.38) LMNAIRAK4
SCHEMBL2803803 0.85 FASN (0.40) ALDH1A1FASNMEN1KMT2ALMNA
SCHEMBL2800861 0.85 TP53 (0.39) ALDH1A1FASNKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 EGLN1 1967/4885RECQL 690/4885ALDH1A1 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.